Cargando…

Protection of Kidney Function with Human Antioxidation Protein α(1)-Microglobulin in a Mouse (177)Lu-DOTATATE Radiation Therapy Model

Aims: Peptide receptor radionuclide therapy (PRRT) is in clinical use today to treat metastatic neuroendocrine tumors. Infused, radiolabeled, somatostatin analog peptides target tumors that are killed by irradiation damage. The peptides, however, are also retained in kidneys due to glomerular filtra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristiansson, Amanda, Ahlstedt, Jonas, Holmqvist, Bo, Brinte, Anders, Tran, Thuy A., Forssell-Aronsson, Eva, Strand, Sven-Erik, Gram, Magnus, Åkerström, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Original Research Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477591/ https://www.ncbi.nlm.nih.gov/pubmed/29943622 http://dx.doi.org/10.1089/ars.2018.7517

Ejemplares similares

Recombinant α(1)-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a (177)Lu-DOTATATE Mouse Radiation Model
por: Alattar, Abdul Ghani, et al.
Publicado: (2023)

(177)Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α(1)-Microglobulin (A1M), Including Kidney Damage Assessment Using (99m)Tc-MAG3 Imaging
por: Kristiansson, Amanda, et al.
Publicado: (2021)

Renal function affects absorbed dose to the kidneys and haematological toxicity during (177)Lu-DOTATATE treatment
por: Svensson, Johanna, et al.
Publicado: (2015)

Kidney Protection with the Radical Scavenger α(1)-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy
por: Kristiansson, Amanda, et al.
Publicado: (2021)

Hematological Toxicity in Mice after High Activity Injections of (177)Lu-PSMA-617
por: Kristiansson, Amanda, et al.
Publicado: (2022)

Human Anti-Oxidation Protein A1M—A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy
por: Ahlstedt, Jonas, et al.
Publicado: (2015)

Co-administration with A1M does not influence apoptotic response of (177)Lu-octreotate in GOT1 neuroendocrine tumors
por: Rassol, Nishte, et al.
Publicado: (2023)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Structure, Functions, and Physiological Roles of the Lipocalin α(1)-Microglobulin (A1M)
por: Bergwik, Jesper, et al.
Publicado: (2021)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020)

Tissue dose estimation after extravasation of (177)Lu-DOTATATE
por: Tylski, Perrine, et al.
Publicado: (2021)

Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
por: Zahid, Anza, et al.
Publicado: (2021)

p53-Mediated Radiosensitization of (177)Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Lundsten, Sara, et al.
Publicado: (2021)

Repurposed Effect of (177)Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
por: Elajami, Mohamad K., et al.
Publicado: (2022)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Evaluation of two intraoperative gamma detectors for assessment of (177)Lu activity concentration in vivo
por: Sandblom, Viktor, et al.
Publicado: (2017)

Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE
por: Pettersson, Olof Joakim, et al.
Publicado: (2021)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

The Role of α(1)-Microglobulin (A1M) in Erythropoiesis and Erythrocyte Homeostasis—Therapeutic Opportunities in Hemolytic Conditions
por: Kristiansson, Amanda, et al.
Publicado: (2020)

IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN (177)LU-DOTATATE TREATMENTS
por: Magnander, Tobias, et al.
Publicado: (2016)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [(177)Lu]Lu-DOTATATE
por: Malcolm, Javian C., et al.
Publicado: (2022)

Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
por: Mitjavila, Mercedes, et al.
Publicado: (2023)

rA1M-035, a Physicochemically Improved Human Recombinant α(1)-Microglobulin, Has Therapeutic Effects in Rhabdomyolysis-Induced Acute Kidney Injury
por: Åkerström, Bo, et al.
Publicado: (2019)

Accuracy and precision assessment for activity quantification in individualized dosimetry of (177)Lu-DOTATATE therapy
por: Marin, Gwennaëlle, et al.
Publicado: (2017)

Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
por: Abou Jokh Casas, Estephany, et al.
Publicado: (2020)

Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale
por: Hallqvist, Andreas, et al.
Publicado: (2021)

Lutathera(®) Orphans: State of the Art and Future Application of Radioligand Therapy with (177)Lu-DOTATATE
por: Urso, Luca, et al.
Publicado: (2023)

Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume
por: Svensson, Johanna, et al.
Publicado: (2016)

Estimation of absorbed dose to the kidneys in patients after treatment with (177)Lu-octreotate: comparison between methods based on planar scintigraphy
por: Larsson, Maria, et al.
Publicado: (2012)

Hyperfractionated Treatment with (177)Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model
por: Elvborn, Mikael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q86ro37clsdht86nauos17kplp